首页|期刊导航|中华医学杂志（英文版）|Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering:current evidence,clinical implications,and future perspectives

Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering:current evidence,clinical implications,and future perspectives

Xin Zhou Ziping Li Hangkuan Liu Yongle Li Dong Zhao Qing Yang

中华医学杂志（英文版）2023，Vol.136Issue(6)：645-652,8.

中华医学杂志（英文版）2023，Vol.136Issue(6)：645-652,8.DOI:10.1097/CM9.0000000000002057

Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering:current evidence,clinical implications,and future perspectives

Xin Zhou ¹Ziping Li ¹Hangkuan Liu ¹Yongle Li ¹Dong Zhao ²Qing Yang¹

作者信息

1. Department of Cardiology,Tianjin Medical University General Hospital,Tianjin 300052,China
2. Department of Epidemiology,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,Institute of Heart,Lung and Blood Vessel Diseases,Beijing 100029,China
折叠

摘要

关键词

Cholesterol-lowering drugs/Bleeding/Antithrombotic/LDL cholesterol/Proprotein convertase subtilisin/kexin type 9 inhibitors

Key words

Cholesterol-lowering drugs/Bleeding/Antithrombotic/LDL cholesterol/Proprotein convertase subtilisin/kexin type 9 inhibitors

引用本文复制引用

Xin Zhou,Ziping Li,Hangkuan Liu,Yongle Li,Dong Zhao,Qing Yang..Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering:current evidence,clinical implications,and future perspectives[J].中华医学杂志（英文版）,2023,136(6):645-652,8.

基金项目

This work was supported by grants from the National Key Research and Experimental Development Program of China(Nos.2020YFC2004700 and 2020YFC2004706),the National Natural Science Foundation of China(No.81970304),and the Tianjin Municipal Science and Technology Commission(No.18ZXZNSY00290). （Nos.2020YFC2004700 and 2020YFC2004706）

中华医学杂志（英文版）

OACSCDCSTPCDMEDLINE

ISSN：0366-6999

访问量0

下载量0

段落导航